Physician profile
Stephen B Bharucha
NPI 1912913542
$12,544.06
in general payments reported to CMS, 2019-2025
34 companies · $2,000 in 2025
The $2,000 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,719 · 2020: $1,387 · 2021: $1,978 · 2022: $1,684 · 2023: $1,775 · 2024: $2,001 · 2025: $2,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,775.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,366.04 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $2,408.99 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $1,083.01 | 2019-2025 | Entyvio |
| Ardelyx, INC. | $910.58 | 2022-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $830.65 | 2019-2024 | Linzess |
| Janssen Biotech, INC. | $651.05 | 2019-2024 | Stelara, Tremfya |
| Merck Sharp & Dohme LLC | $542.18 | 2019-2024 | Dificid |
| Celgene Corporation | $449.73 | 2021-2024 | Zeposia |
| Redhill Biopharma INC. | $429.04 | 2020-2024 | Talicia, Movantik, Aemcolo |
| Nestle Healthcare Nutrition INC. | $310.38 | 2020-2023 | |
| Allergan, INC. | $231.71 | 2019 | |
| Pfizer INC. | $218.29 | 2019-2024 | |
| Qol Medical, LLC | $196.06 | 2021-2025 | Sucraid, Sucraid |
| Cumberland Pharmaceuticals, INC. | $189.37 | 2022-2025 | Kristalose |
| Aimmune Therapeutics, INC. | $105.48 | 2024-2025 | Zenpep, Vowst |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $94.13 | 2019-2024 | |
| Ferring Pharmaceuticals INC. | $85.01 | 2020 | |
| Exact Sciences Corporation | $61.75 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Alnylam Pharmaceuticals INC. | $57.62 | 2023 | Givlaari |
| Ucb, INC. | $51.45 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $34.41 | 2025 | Dupixent |
| Novo Nordisk INC | $24.95 | 2025 | Wegovy, Saxenda |
| Vivus LLC | $23.45 | 2019 | |
| W. L. Gore & Associates, INC. | $22.90 | 2022 | |
| Mallinckrodt Hospital Products INC. | $21.53 | 2023 | Terlivaz |
| Shire North American Group INC | $19.42 | 2019 | |
| Daiichi Sankyo INC. | $18.76 | 2022 | |
| Medtronic, INC. | $18.64 | 2023 | Gi Genius |
| Phathom Pharmaceuticals, INC. | $16.17 | 2024 | Voquezna |
| Boston Scientific Corporation | $15.09 | 2019 | |
| Braintree Laboratories, INC. | $14.90 | 2019 | |
| Intercept Pharmaceuticals, INC. | $14.56 | 2023 | Ocaliva |
| E.R. Squibb & Sons, L.L.C. | $13.57 | 2021 | |
| Celltrion USA INC. | $13.19 | 2024 | Vegzelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Bharucha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.